Company Profile

DIVIS LABORATORIES LTD.

NSE : DIVISLABBSE : 532488ISIN CODE : INE361B01024Industry : Pharmaceuticals & DrugsHouse : Divis Labs
BSE3570.8026.4 (+0.74 % )
PREV CLOSE (Rs.) 3544.40
OPEN PRICE (Rs.) 3560.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 17744
TODAY'S LOW / HIGH (Rs.)3482.55 3588.00
52 WK LOW / HIGH (Rs.)1632.7 3913
NSE3569.05 24.35 (+0.69 % )
PREV CLOSE(Rs.) 3544.70
OPEN PRICE (Rs.) 3562.00
BID PRICE (QTY) 3569.05 (64 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 926197
TODAY'S LOW / HIGH(Rs.) 3481.70 3589.40
52 WK LOW / HIGH (Rs.)1626 3914.95

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.01
Dividend Yield(%) 0.45
TTM EPS (Rs.) 66.23
P/E Ratio 53.92
Book Value (Rs.) 313.47
Face Value (Rs.) 2
MCap (Rs. in Mn) 947935.21
Price/Earning (TTM) 48.09
Price/Sales (TTM) 15.31
Price/Book (MRQ) 11.39
PAT Margin (%) 25.85
ROCE (%) 25.23
Incorporation Year : 1990

Management Info :

Ramesh BV Nimmagadda - Chairman Murali K Divi - Managing Director

Registered Office :

Address : 1-72/23(p)/divis/303,Divi Towers, Cyber Hills,Gachibowli,
Hyderabad,
Telangana-500032

Phone : 040 2378 6300

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
07Jan01-07-2021$Divis Laboratories informs about certificate Divis Laboratories informs a

Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, Divis Laboratories has submitted the certificate received from KFin Technologies, Registrar & Share Transfer Agent of the Company, dated 06 January, 2021, for the quarter ended 31st December, 2020.

The above information is a part of company’s filings submitted to BSE.


Pursuant to Regulation 74(5) of SEBI (Depositories and Particip..
01Dec12-01-2020$Divi’s Laboratories to commence construction at unit-III Andhra Pradesh facility Divi’s Laboratories to com

Divi’s Laboratories is planning to commence construction of its unit-III facility at Kona Forest, Ontimamidi Village, Andhra Pradesh from the December 07, 2020. The Company will be investing about Rs 1500 crore out of its internal accruals in phased manner for the implementation of its Unit III facility. The operations are likely to commence within 12 to 18 months for 1st phase of the Project. All the requisite licenses have been granted by the Government of India and Government of Andhra Pradesh for implementation of the Project.

Divi’s Laboratories focused on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates.

Divi’s Laboratories is planning to commence construction of i..
01Dec12-01-2020$Divi’s Laboratories gains on the BSE Divi’s Laboratories gains

Divi’s Laboratories is currently trading at Rs. 3625.00, up by 17.40 points or 0.48% from its previous closing of Rs. 3607.60 on the BSE.

The scrip opened at Rs. 3760.00 and has touched a high and low of Rs. 3760.00 and Rs. 3599.75 respectively. So far 73984 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 3,760.00 on 01-Dec-2020 and a 52 week low of Rs. 1632.70 on 19-Mar-2020.

Last one week high and low of the scrip stood at Rs. 3760.00 and Rs. 3450.00 respectively. The current market cap of the company is Rs. 96134.14 crore.

The promoters holding in the company stood at 51.96%, while Institutions and Non-Institutions held 37.08% and 10.96% respectively.

Divi’s Laboratories is planning to commence construction of its unit-III facility at Kona Forest, Ontimamidi Village, Andhra Pradesh from the December 07, 2020. The Company will be investing about Rs 1500 crore out of its internal accruals in phased manner for the implementation of its Unit III facility. The operations are likely to commence within 12 to 18 months for 1st phase of the Project. All the requisite licenses have been granted by the Government of India and Government of Andhra Pradesh for implementation of the Project.

Divi’s Laboratories focused on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates.

Divi’s Laboratories is currently trading at Rs. 3625.00, up b..
27Oct10-27-2020$Divi’s Laboratories board to approve unaudited financial results Divi’s Laboratories board

Divi’s Laboratories has informed that the meeting of the Board of Directors of the Company is scheduled on 07/11/2020, to consider and approve the standalone and consolidated unaudited financial results for the quarter and half year ended 30 September, 2020. As intimated earlier, the Trading Window for dealing in securities of the Company has been closed from 01 October, 2020 till 48 hours after the declaration of financial results as per the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.

Divi’s Laboratories has informed that the meeting of the Boar..
16Sep09-16-2020$Divis Laboratories informs about clarification regarding the news Divis Laboratories informs a

With reference to various new channels telecasting news about ‘Divi's Laboratories acquiring stake in SMS Pharmaceuticals’. Divis Laboratories has informed that it has denied the news being circulated. Neither the Company nor the promoters have any intention or plans or discussions to acquire stake in SMS Pharmaceuticals or any of its group companies. The Company has always been relying on organic growth.

The above information is a part of company’s filings submitted to BSE.

With reference to various new channels telecasting news about â..
Financials More
Rs. in Millions
QTR Sep 20 ANNUAL 20
Net Profit513313727.1
Gross Profit 6850.3 18132.9
Operating Profit 7460.320053
Net Sales 17137.853105.7
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 14535.90 (0.84%)
M.Cap ( in Cr)
30887.77
Alkem Laboratories (BSE)
 3110.05 (2.51%)
M.Cap ( in Cr)
37185.31
Aurobindo Pharma (BSE)
 998.00 (8.05%)
M.Cap ( in Cr)
58476.67
JB Chem & Pharma (BSE)
 1046.45 (5.34%)
M.Cap ( in Cr)
8087.19
Dr. Reddys Lab (BSE)
 5082.10 (0.96%)
M.Cap ( in Cr)
84514.37
Shareholding Pattern More
PROMOTERS 51.95 %
FII 20.37 %
MUTUAL FUNDS/UTI 13.19 %
NON-INSTITUTION 10.83 %
FI/BANKS/INSURANCE 0 %
GOVERNMENT 0 %
F & O Quotes